Cancer immunotherapy
PRINCIPAL INVESTIGATORS
- Rafael Moreno Olié
CLINICAL RESEARCHERS
- Oscar Buisán Rueda
- Claudio Rocha Calderon
POSTDOCTORAL RESEARCHERS
- Marcel Costa Garcia
- Maria Dolores Lopez Robles
- Rafael Moreno Olié
- Gabriel Espinosa Carrasco
PREDOCTORAL RESEARCHERS
- Luis Paul Del Carpio Huerta
- Laura Moya Borrego
- Sebastian Ciro Carne Martin
- Pau Fiol Mata
- Juan Antonio Marin Jimenez
SCIENTIFIC SUPPORT
- Carles Codony Servat
- Silvia Torres Manjon
- Paz Moreno Serrano
- Ana Maria Torrent Moreno
- Ainhoa Muñoz Metrino
Cancer
Oncobell
Scientific production
20
PAPERS
Average IF: 27,733
7
LED PAPERS
Average IF: 13,243
8 PUBLICATIONS IN FIRST DECILE
14 PUBLICATIONS IN FIRST QUARTILE
17 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Fizazi,K;Piulats,JM;Reaume,MN;Ostler,P;McDermott,R;Gingerich,JR;Pintus,E et al, Rucaparib or Physician’s Choice in Metastatic Prostate Cancer., N. Engl. J. Med., 2023;388(8):719-732, doi:10.1056/NEJMoa2214676
- Hassel,JC;Piperno Neumann,S;Rutkowski,P;Baurain,JF;Schlaak,M;Butler,MO;Sullivan,RJ et al, Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma, N. Engl. J. Med., 2023;389(24):2256-2266, doi:10.1056/NEJMoa2304753
- Piulats,JM;Watkins,C;Costa García,M;Del Carpio,L;Piperno Neumann,S;Rutkowski,P;Hassel,JC et al, Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis., Ann. Oncol., 2023;doi:10.1016/j.annonc.2023.11.013
- Piulats,JM;Watkins,C;Costa García,M;Del Carpio,L;Piperno Neumann,S;Rutkowski,P;Hassel,JC et al, Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis., Ann. Oncol., 2023;doi:10.1016/j.annonc.2023.11.013
- Garofalo,M;Wieczorek,M;Anders,I;Staniszewska,M;Lazniewski,M;Prygiel,M;Zasada,AA et al, Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model, Front. Oncol., 2023;131259314-1259314, doi:10.3389/fonc.2023.1259314
Research highlights
PROJECTS
4 Granted Competitive project
15 Ongoing Competitive projects
4 Started clinical trials
25 Ongoing clinical trials
4 Ongoing non competitive project
INNOVATION
2 Patents
2 Licenses
NETWORKS
RICORS
AGAUR SGR GRC
Adenonet
Selected projects
- 20FIS039. Phase II stUdy of ALoCelyvir in patientS with mEtastatic Uveal Melanoma (PULSE-UM). Instituto de Salud Carlos III (ISCIII). Budget: 694.346,29€. 2020-2025. PI: Piulats Rodríguez, Josep María.
- 21FIS038. Venciendo la resistencia a la inmunoterapia en tumores no antigéncios ni inmunogénicos usando el cáncer de próstata como modelo. El estudio HEAT-CRPC. Instituto de Salud Carlos III (ISCIII). Budget: 133.100€. 2021-2025. PI: Piulats Rodríguez, Josep María.
- FIS21131. RICORS TERAV. Instituto de Salud Carlos III (ISCIII). Budget: 169.412,1€. 2022-2024. PI: Alemany Bonastre, Ramón.
- 2022-160-1. ESTUDIO FASE II, ABIERTO DE LA EFICACIA PRELIMINAR DE SITRAVATINIB EN COMBINACIÓN CON TISLELIZUMAB EN PACIENTES CON MELANOMA METASTÁSICO UVEAL CON HEPÁTICAS METÁSTASIS. Grupo Español Multidisciplinar de Melanoma (GEM). Budget: 5.000€. 2022- . PI: Piulats Rodríguez, Josep María.
- 18ACL149. A PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 USING THE INTRA-PATIENT ESCALATION DOSING REGIMEN IN PATIENTS WITH ADVANCED UVEALMELANOMA. Immunocore Ireland Limited. Budget: 154.384€. 2018- . PI: Piulats Rodríguez, Josep María.